Avodart (dutasteride), a new drug for benign prostatic hyperplasia

December 2002

GlaxoSmithKline is now marketing Avodart (dutasteride), a new drug for benign prostatic hyperplasia.

It's being promoted as better than Proscar (finasteride) because it blocks the two types of 5-alpha reductase.

Proscar selectively blocks only type 2.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter membership benefits include:

12 issues every year — what you need to know and do, right now
Quick, practical reference charts and tools
Comprehensive CE library to meet license renewal and state requirements
Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
Plus much more!

Choose the right tier for your needs today.

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get a quote

Table of Contents

smallpox vaccine program and world events will raise questions
Cardiology Zetia (ze-TEE-a) is now the first "cholesterol absorption inhibitor" for hyperlipidemia
Cardiology using digoxin in WOMEN with heart failure might do more harm than good
Cardiology new approaches for preventing a SECOND heart attack
Diabetes Some diabetes patients are getting into trouble because they think all "clear" insulin is rapid acting
Obesity & Weight Loss Topamax (topiramate) for obesity
Abilify (a-BILA-fī), a new antipsychotic for schizophrenia
When Claritin (loratadine) goes OTC, many insurance plans will stop paying for some prescription antihistamines
Commit Lozenge is the newest OTC option to help smokers quit
allergic reactions to Bextra
Men's Health Avodart (dutasteride), a new drug for benign prostatic hyperplasia
Cholesterol statins do much more than just lower cholesterol
Natural Medicines questions about coral calcium.
Gastroenterology irritable bowel syndrome (IBS) patients can benefit from SSRIs
Gastroenterology GENERIC omeprazole will soon be available
Dermatology duct tape for common warts